---
title: >-
  TARGET PharmaSolutions to Advance Research in NASH and Hepatitis B Through New
  Collaboration with Gilead Sciences
description: >-
  Read the latest news on regulatory-grade real-world evidence: TARGET
  PharmaSolutions to Advance Research in NASH and Hepatitis B Through New
  Collaboration…
date: '2018-11-20'
category: News
tags:
  - Partnership Announcement
  - R&D
  - Approval / Commercialization
  - Hepatology
  - MASH/MASLD
  - HBV
  - Pharma Partner
canonical_url: >-
  https://www.pedestalhealth.com/resources/news/partnership-announcement/target-pharmasolutions-to-advance-research-in-nash-and-hepatitis-b-through-new-collaboration-with-gilead-sciences/
source: Pedestal Health
license: © 2026 Pedestal Health. All rights reserved.
slug: >-
  target-pharmasolutions-to-advance-research-in-nash-and-hepatitis-b-through-new-collaboration-with-gilead-sciences
id: 5gyWjP3bDhXumjTIzQq9eh
contentType: article
---

CHAPEL HILL, NC – November 20, 2018 /[PR NEWSWIRE](https://www.prnewswire.com/news-releases/target-pharmasolutions-to-advance-research-in-nash-and-hepatitis-b-through-new-collaboration-with-gilead-sciences-300753160.html)/ – TARGET PharmaSolutions, Inc., a company focused on real world evidence, is pleased to announce that it has entered into a strategic partnership with Gilead Sciences for TARGET-NASH and TARGET-HBV. Gilead is the sixth partner in TARGET-NASH, joining Allergan, Boehringer Ingelheim, Bristol-Myers Squibb, Intercept and Novartis, and the first partner to join TARGET-Hepatitis B.

TARGET-NASH is a robust, meticulously-documented, longitudinal observational study that evaluates adult and pediatric patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH). TARGET-NASH has enrolled over 4,250 patients to date and will enroll up to 15,000 patients in total over the coming years.  TARGET-NASH is led by an academic steering committee chaired by Drs. Arun Sanyal, MD (Virginia Commonwealth University); Ken Cusi, MD (University of Florida), and Brent Tetri (Saint Louis University).

The academic steering committee co-chair, Dr. Arun Sanyal, MD stated “TARGET-NASH is critical for the scientific and regulatory community as we prepare for the plethora of new agents for the treatment of NASH.  In the immediate term, it will give us a critical understanding of NASH diagnosis and management in the real world across multiple populations.  In the longer term, it is the perfect platform to have a deep understanding of the safety and effectiveness of these new agents across populations not included or underrepresented in Phase 3 clinical trials.”

TARGET-HBV is an observational study that is evaluating patients with Hepatitis B.  TARGET-HBV recently started enrolling patients and plans to enroll up to 5,000 patients across a diverse network of sites to advance our understanding of Hepatitis B.

Meg Powell, Pharm.D., CEO of TARGET PharmaSolutions, stated “We are very excited to have Gilead join TARGET-NASH and TARGET-HBV.  It is a privilege to partner with a company so focused on advancing the understanding of Liver Diseases.”